In line with this observation, it has been shown that the use of an antagonist peptide that would disrupt N-cadherin interactions between BM and chronic myeloid leukemia (CML) cells increases the sensitivity to imatinib [117]. The gene discussed is CDH2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.